Amgen, Inc. (AMGN) announced Thursday a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
The $1 billion facility will incorporate cutting-edge technologies and sustainable practices, aligning with Amgen's commitment to environmental stewardship and manufacturing excellence.
In tandem with the existing facility, these investments will create 370 new jobs in the region, supporting a robust biomanufacturing hub.
This expansion enhances the company's global biomanufacturing network, leveraging decades of operational expertise and technological advancements to ensure the reliable and efficient delivery of high-quality medicines to patients worldwide.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.